MDNAF (Medicenna Therapeutics) Cyclically Adjusted FCF per Share: $-0.23 (As of Mar. 2026)


MDNAF Medicenna Therapeutics Corp MDNAF
30 GF Score
Price $0.26
! 1 Warning Sign
View Full Analysis

What is Medicenna Therapeutics Cyclically Adjusted FCF per Share?

Medicenna Therapeutics MDNAF -2.61% 30 Cyclically Adjusted FCF per Share is $-0.23 as of Mar. 2026. GuruFocus rates MDNAF with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Medicenna Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-0.039. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-0.23 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-13), Medicenna Therapeutics's current stock price is $0.2608. Medicenna Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-0.23. Medicenna Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Medicenna Therapeutics  (OTCPK:MDNAF) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Medicenna Therapeutics Cyclically Adjusted FCF per Share Related Terms


Medicenna Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Medicenna Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicenna Therapeutics Cyclically Adjusted FCF per Share Chart

Medicenna Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.23 -0.23

Medicenna Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.23 -0.24 -0.23 -0.24 -0.23

MDNAF vs VRTX, REGN, ALNY: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Medicenna Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicenna Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medicenna Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Medicenna Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


MDNAF
30GF Score
Medicenna Therapeutics Corp MDNAF
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medicenna Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Medicenna Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.039/132.2623*132.2623
=-0.039

Current CPI (Mar. 2026) = 132.2623.

Medicenna Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.056 102.002 -0.073
201609 -0.006 101.765 -0.008
201612 0.000 101.449 0.000
201703 -0.085 102.634 -0.110
201706 -0.056 103.029 -0.072
201709 -0.073 103.345 -0.093
201712 -0.102 103.345 -0.131
201803 -0.095 105.004 -0.120
201806 -0.073 105.557 -0.091
201809 -0.049 105.636 -0.061
201812 -0.062 105.399 -0.078
201903 -0.053 106.979 -0.066
201906 -0.068 107.690 -0.084
201909 0.051 107.611 0.063
201912 -0.048 107.769 -0.059
202003 -0.052 107.927 -0.064
202006 -0.038 108.401 -0.046
202009 -0.102 108.164 -0.125
202012 -0.064 108.559 -0.078
202103 -0.033 110.298 -0.040
202106 -0.070 111.720 -0.083
202109 -0.137 112.905 -0.160
202112 -0.098 113.774 -0.114
202203 -0.041 117.646 -0.046
202206 -0.032 120.806 -0.035
202209 -0.052 120.648 -0.057
202212 -0.039 120.964 -0.043
202303 -0.024 122.702 -0.026
202306 -0.037 124.203 -0.039
202309 -0.042 125.230 -0.044
202312 -0.043 125.072 -0.045
202403 -0.051 126.258 -0.053
202406 -0.023 127.522 -0.024
202409 -0.054 127.285 -0.056
202412 -0.032 127.364 -0.033
202503 -0.045 129.181 -0.046
202506 -0.031 129.892 -0.032
202509 -0.043 130.287 -0.044
202512 -0.043 130.366 -0.044
202603 -0.039 132.262 -0.039

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-0.23 mean?
Medicenna Therapeutics (MDNAF) has a Cyclically Adjusted FCF per Share of $-0.23 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Medicenna Therapeutics and its competitors.
Is Medicenna Therapeutics' Cyclically Adjusted FCF per Share too high?
Medicenna Therapeutics' current Cyclically Adjusted FCF per Share is $-0.23. Overall, Medicenna Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Medicenna Therapeutics' Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Medicenna Therapeutics' Cyclically Adjusted FCF per Share of $-0.23 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Medicenna Therapeutics and its competitors. Medicenna Therapeutics's current Cyclically Adjusted FCF per Share is $-0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicenna Therapeutics stock overvalued right now?
Medicenna Therapeutics (MDNAF) has a current Cyclically Adjusted FCF per Share of $-0.23. The current Cyclically Adjusted FCF per Share is $-0.23. Medicenna Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Medicenna Therapeutics (MDNAF), the current Cyclically Adjusted FCF per Share is $-0.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medicenna Therapeutics Business Description

Other Exchanges MDNA:Canada
Address 2 Bloor Street West, Suite 903, Toronto, ON, CAN, M4W 3E2
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL-13 Superkines and Empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. Its pipeline candidates include MDNA11 for Cancer immunotherapies, MDNA55 is a Molecular Trojan Horse, and BiSKITs represent a novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
30GF Score

Get the complete analysis for MDNAF

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.26
Price